This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Armodafinil
R-enantiomer-only modafinil with smoother monophasic decline, ~33-40% higher AUC mg-for-mg, and Tmax 3-4 hr later than racemic modafinil.
Aliases (6)
Overview
What is Armodafinil?
Armodafinil (brand name Nuvigil) is the R-enantiomer of modafinil, FDA-approved for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea. It has a longer effective half-life than racemic modafinil at equivalent doses.
Key Benefits
Sustained wakefulness and cognitive performance with smoother peak-to-trough kinetics than modafinil, reduced fatigue under sleep deprivation, and a longer duration of action — useful for long shifts and afternoon coverage.
Mechanism of Action
Same mechanism as modafinil: dopamine transporter inhibition, elevated orexinergic and histaminergic tone. Higher peak plasma concentration and longer effective duration than racemic modafinil at equivalent doses.
Pharmacokinetics
▸Brand options5 known
StatusSchedule IV (US, DEA); Prescription-only (EU, UK, AU, CA)
Research Indications
Weak dopamine transporter (DAT) inhibitor
competitive binding raises extracellular DA in striatum and prefrontal cortex without causing the sharp DA spikes seen with amphetamines …
Indirect orexin/hypocretin activation
R-modafinil does not bind orexin receptors directly, but raises orexinergic tone via D1 receptor activation in lateral hypothalamus, wher…
Indirect histamine release
orexin neurons project to tuberomammillary nucleus histamine neurons; modafinil-induced wakefulness requires intact orexin neurons to ele…
Glutamatergic potentiation
produces long-term potentiation of glutamatergic transmission in cortex.
Mild norepinephrine + serotonin effects
secondary to the multi-system arousal cascade.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(low dose, 50-100 mg): Adenosine antagonism is mechanistically additive to dopamine/orexin/histamine arousal. the user's baseline has zero caffeine, so 50 mg…
Smooths the alerting edge, no efficacy compromise.
Different mechanism (mild DA + 5-HT + DAT, anti-asthenic). Stacks cleanly per Russian eugeroic protocols. This is part of the canonical stack plan.
Cholinergic substrate support for the cognitive load that modafinil-class drugs let you sustain.
(if Rx-path): 6 RCTs back modafinil + bupropion for depression/fatigue; same mechanism logic applies to armodafinil + bupropion.
General brain substrate; no interaction.
Hypertensive crisis risk. Note for users in this archetype: Selegiline 1-2.5 mg/day is MAO-B selective only and clinically considered safe with modafinil-cla…
Stacking dopaminergic stimulants → overstimulation, cardiovascular load, anxiety, sleep wreck. Pick one.
3 dopaminergic agents = overstimulation risk per encyclopedia.
Redundant + AUC stacking. Pick one wakefulness anchor.
CYP3A4 induction reduces effectiveness ~18%.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 11
Side Effects
- 1Headache (~25-30% incidence; often first-dose, fades after 1-2 weeks)
- 2Insomnia/sleep disturbance (~14% in 12-month data; higher in late-day dosing)
- 3Nausea (~5-10%)
- 4Dizziness (~5%)
- 5Dry mouth / xerostomia (~5-10%)
- 6Anxiety / irritability
- 7Decreased appetite
- 8Diarrhea
- 9Palpitations / mild HR elevation (~6-7 bpm average)
- 10Mild BP elevation (~3-4 mmHg systolic, ~2 mmHg diastolic)
- 11Depression (more frequent at 250 mg vs 150 mg per drugs.com side effect data)
When to Stop
- Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): Life-threatening skin reaction. Documented case reports for armodafinil specifically (PMC5940442, Khanna et al. 2018). Median onset 13 days from drug initiation. Range 1 day to 2 months, rarely beyond 3 months. Higher relative risk in pediatrics (0.8% rash incidence in <17yo). For adult population, estimated incidence ~1/5000 to 1/10000.
- Anaphylaxis / angioedema — rare immune-mediated reaction.
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) — rare.
- Suicidal ideation, mania, hallucinations — rare; psych history caution.
- Hypertensive crisis — only with concurrent MAOI (tranylcypromine, phenelzine).
- Weeks 1-8: SJS surveillance window. Any rash, mouth ulcer, mucosal blistering, fever + skin involvement → STOP IMMEDIATELY and seek care. Most SJS cases manifest within 6 weeks.
- Weeks 1-12: BP/HR adjustment window. Cardiovascular changes plateau by month 3. Track resting HR via Oura, periodic BP cuff.
- First 4 weeks: Sleep architecture stabilization. Some sleep disruption is expected; if persistent at week 4 with morning dosing, dose may be too high or too late.
References
Darwish et al. 2009 — Armodafinil and Modafinil Have Substantially Different Pharmacokinetic Profiles Despite Having the Same Terminal Half-Lives (PMID 19663523)
pooled analysis of 3 RCT PK studies; 33-40% AUC difference established
View StudyDarwish et al. 2010 — PK of armodafinil and modafinil in OSA crossover study (PMID 21118743)
single + multiple dose; armodafinil 200 AUC vs modafinil 200 AUC; monophasic vs biphasic decline
View StudyDarwish et al. 2009 — Pharmacokinetic Profile of Armodafinil in Healthy Subjects (PMID 19133704)
pooled healthy-subject PK; Tmax, Cmax, food effect
View StudyTembe et al. 2011 — Armodafinil 150 vs Modafinil 200 in shift work disorder RCT (PMID 21766023)
clinical equipotency confirmed
View StudyBlack et al. 2010 — Long-term tolerability and efficacy of armodafinil 12-month open-label extension (JCSM)
n=743, no tolerance, AE profile, BP/HR effects plateau by month 3
View StudyKhanna et al. 2018 — Stevens-Johnson Syndrome After Armodafinil Use (PMC5940442)
case report; SJS onset window data
View StudyNUVIGIL FDA label 2017 (accessdata.fda.gov)
official FDA prescribing information with 2017 SJS warning update
View StudyRobertson & Hellriegel 2003 — Clinical pharmacokinetic profile of modafinil (DrugBank summary)
context for racemic vs enantiomer PK
View StudyDarwish et al. 2008 — Interaction profile of armodafinil with CYP1A2, 3A4, 2C19 (PMID 18076219)
moderate CYP3A4 induction, moderate CYP2C19 inhibition documented
View StudyGreenblatt et al. 2021 — CYP3A4 contraceptive failure adverse event analysis (PMC7972989)
contraceptive interaction route-of-administration analysis
View StudyBeck et al. 2024 — Pregnancy and Fetal Outcomes Following Prenatal Exposure to Modafinil/Armodafinil 14-year registry (Neurology Clinical Practice 2025)
13-17% MCM rate vs 3% baseline; international regulatory action since 2019
View StudyPublic Citizen FDA Petition — modafinil/armodafinil pregnancy contraindication
context on FDA lag vs international regulators
View StudyPsychSceneHub — Modafinil and Armodafinil Mechanism of Action review
mechanism integration across DA, orexin, histamine, glutamate
View StudyFrontiers Pharmacology 2025 — Stable interindividual differences in modafinil's effect on vigilance during sleep deprivation (Hansen et al.)
between-subject response variation
View StudyFrontiers Neuroanatomy 2025 — Functional neuroanatomy of dopaminergic arousal systems and modafinil
recent mechanism update
View StudyWisor 2013 — R-modafinil unique DAT inhibitor profile (PMC3413742)
R-enantiomer pharmacology specifics
View StudyBuyModa — HighStreetPharma Vendor Test 2026
2026 anonymous test order audit
View StudyBuyModa — Titans of Modafinil 2026 vendor landscape
current operational vendor list incl. BuyModa closure May 2025
View StudyModafinil.org — Best modafinil vendors April 2026
vendor reliability cross-reference
View StudyRusso 2009 — Pharmacotherapy of Excessive Sleepiness: Focus on Armodafinil (Sage)
clinical review
View StudyBlack 2010 — Armodafinil in treatment of sleep/wake disorders review (PMC2938291)
clinical context
View StudyDrugs.com — Armodafinil dosage and side effects
dosing reference, side effect frequencies
View StudyGBC Health — Armodafinil vs Modafinil comparison
practical comparison summary
View StudyGreen Door — Artvigil vs Waklert comparison
Sun Pharma vs HAB Pharma generic comparison
View StudyNootropicology — Armodafinil nootropic review
nootropic-community context
View StudyLatest research
- rctStable interindividual differences in modafinil's effect on vigilance during sleep deprivationSame person responds consistently across exposures; between-person modafinil response varies substantially.
- observationalPregnancy and Fetal Outcomes Following Prenatal Exposure to Modafinil/Armodafinil — 14-yr registry13-17% major congenital malformation rate vs 3% baseline; international regulators contraindicated since 2019.
- reviewFunctional neuroanatomy of dopaminergic arousal systems and modafinilUpdated mechanism synthesis across DAT, orexin, histamine, and glutamate arousal pathways.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.